REDOSE, NCT03927391: Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects |
|
|
| Completed | 4 | 57 | Europe | Enzalutamide | Radboud University Medical Center | Prostatic Neoplasms, Castration-Resistant | 01/24 | 01/24 | | |
ANZadapt, NCT05393791: Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC |
|
|
| Recruiting | 2 | 168 | Europe, RoW | Patient-specific adaptive therapy, Abiraterone acetate, Zytiga, Enzalutamide, Xtandi | Leiden University Medical Center, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Anticancer Fund, Belgium | Prostatic Neoplasms, Castration-Resistant | 11/27 | 11/27 | | |
MIND THE GAP, NCT05339672: Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban |
|
|
| Recruiting | N/A | 26 | Europe | Blood sampling - Pharmacokinetic assessment | Radboud University Medical Center, Astellas Pharma Inc | Drug-drug Interaction | 08/24 | 08/24 | | |